Serajee Fatema J, Huq Ahm M
Department of Pediatrics and Neurology, Wayne State University, Detroit, Michigan.
Department of Pediatrics and Neurology, Wayne State University, Detroit, Michigan.
Pediatr Neurol. 2015 Jun;52(6):642-6.e1. doi: 10.1016/j.pediatrneurol.2015.02.011. Epub 2015 Mar 13.
Synaptic vesicle protein 2A (SV2a) is the binding site of the antiepileptic drug levetiracetam and the only known synaptic vesicle target of an epilepsy medication. To date, no pathogenic mutation in SV2A, which is the gene encoding synaptic vesicle glycoprotein 2A, has been identified in humans. We report a homozygous mutation in the SV2A gene in a patient with intractable epilepsy.
We investigated a patient with intractable epilepsy, involuntary movements, microcephaly, and developmental and growth retardation. Both parents were multiply consanguineous and an earlier-born brother of the proband had a similar course and died at 7 months of age. Detailed clinical history, imaging, electroencephalograph and metabolic testing were obtained. Full exome sequencing was performed using genomic DNA isolated from the patient and both parents.
Exome sequencing identified a homozygous arginine to glutamine mutation in amino acid position 383 (R383Q) in exon 5 of the SV2A gene. Both parents were carriers for the R383Q variant, suggesting that R383Q is a recessive mutation. There were no other candidate alterations in the exome that could explain the phenotype in the proband. The amino acid arginine at position 383 of SV2a gene is evolutionally conserved throughout vertebrates. R383Q change is not observed in known healthy cohorts, exome databases, or the Database of Single Nucleotide Polymorphisms. The R383Q mutation is located in the second adenine binding domain in SV2a protein and may alter adenine nucleotides binding to SV2a.
Our report provides the elusive evidence that an SV2A mutation can be a cause of epilepsy in humans. Levetiracetam, which binds to SV2A, was not effective as an antiepileptic medication. The location of the mutation in our patient supports an important role of adenine nucleotides binding in SV2A function.
突触囊泡蛋白2A(SV2A)是抗癫痫药物左乙拉西坦的结合位点,也是已知的唯一一种癫痫药物的突触囊泡靶点。迄今为止,在人类中尚未发现编码突触囊泡糖蛋白2A的基因SV2A存在致病突变。我们报告了一名难治性癫痫患者中SV2A基因的纯合突变。
我们对一名患有难治性癫痫、不自主运动、小头畸形以及发育和生长迟缓的患者进行了研究。患者的父母为近亲结婚,先证者的一个早出生的兄弟有类似病程并在7个月大时死亡。我们获取了详细的临床病史、影像学检查、脑电图和代谢检测结果。使用从患者及其父母分离的基因组DNA进行全外显子组测序。
外显子组测序在SV2A基因第5外显子的第383位氨基酸处鉴定出一个精氨酸到谷氨酰胺的纯合突变(R383Q)。父母双方均为R383Q变异的携带者,这表明R383Q是一个隐性突变。外显子组中没有其他候选改变能够解释先证者的表型。SV2A基因第383位的精氨酸在整个脊椎动物中具有进化保守性。在已知的健康队列、外显子组数据库或单核苷酸多态性数据库中均未观察到R383Q改变。R383Q突变位于SV2a蛋白的第二个腺嘌呤结合结构域,可能会改变腺嘌呤核苷酸与SV2a的结合。
我们的报告提供了难以获得的证据,即SV2A突变可能是人类癫痫的一个病因。与SV2A结合的左乙拉西坦作为抗癫痫药物无效。我们患者中突变位点的位置支持腺嘌呤核苷酸结合在SV2A功能中起重要作用。